
|Articles|January 24, 2005
BREAKING NEWS...
The black eye the FDA received recently over its handling of Vioxx (rofecoxib, Merck) and antidepressants hasn't slowed the agency's new drug approval rate for 2004. It cleared 31 new molecular entities (NMEs) last year, up from 21 in 2003.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Addressing Depression Symptoms Can Significantly Improve Asthma Outcomes
2
President Trump Signs Sweeping, Unprecedented Federal PBM Reform
3
What the Newest Landmark PBM Reform Means for the Pharmacy Industry
4
TrumpRx Officially Launches, Introduces Drug Prices
5























